Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of September 30, 2017:
- Issued Share Capital: 5,371,837,120 ordinary shares of 25 pence each.
- Treasury Shares: 453,205,950 ordinary shares held in Treasury.
- Total Voting Rights: 4,918,631,170.
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,918,631,170) against the latest regulatory filings to ensure accurate calculation of ownership thresholds.
- Confirm the number of shares held in Treasury (453,205,950) to understand the difference between issued capital and outstanding voting shares.
- Note that this filing does not contain financial results; investors should refer to the Company's Form 20-F or interim reports for financial performance data.